Infinity Pharmaceuticals Stock Current Asset
| INFIDelisted Stock | USD 0.13 0.01 7.14% |
Infinity Pharmaceuticals fundamentals help investors to digest information that contributes to Infinity Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Infinity Stock. The fundamental analysis module provides a way to measure Infinity Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Infinity Pharmaceuticals stock.
Infinity |
Infinity Pharmaceuticals Company Current Asset Analysis
Infinity Pharmaceuticals' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Infinity Pharmaceuticals Current Asset | 254.7 M |
Most of Infinity Pharmaceuticals' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Infinity Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
CompetitionIn accordance with the recently published financial statements, Infinity Pharmaceuticals has a Current Asset of 254.7 M. This is 88.16% lower than that of the Biotechnology sector and 75.99% lower than that of the Health Care industry. The current asset for all United States stocks is 97.27% higher than that of the company.
Infinity Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Infinity Pharmaceuticals' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Infinity Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Infinity Pharmaceuticals by comparing valuation metrics of similar companies.Infinity Pharmaceuticals is currently under evaluation in current asset category among its peers.
Infinity Fundamentals
| Return On Equity | -35.21 | |||
| Return On Asset | -0.61 | |||
| Operating Margin | (15.70) % | |||
| Current Valuation | (9.46 M) | |||
| Shares Outstanding | 90.76 M | |||
| Shares Owned By Insiders | 2.36 % | |||
| Shares Owned By Institutions | 23.48 % | |||
| Number Of Shares Shorted | 2.21 M | |||
| Price To Earning | (1.63) X | |||
| Price To Book | 8.03 X | |||
| Price To Sales | 19.29 X | |||
| Revenue | 2.59 M | |||
| Gross Profit | (31.38 M) | |||
| EBITDA | (44.84 M) | |||
| Net Income | (44.37 M) | |||
| Cash And Equivalents | 56.58 M | |||
| Cash Per Share | 0.63 X | |||
| Total Debt | 917 K | |||
| Debt To Equity | 0.13 % | |||
| Current Ratio | 4.16 X | |||
| Book Value Per Share | (0.41) X | |||
| Cash Flow From Operations | (42.43 M) | |||
| Short Ratio | 0.31 X | |||
| Earnings Per Share | (0.45) X | |||
| Price To Earnings To Growth | (0.05) X | |||
| Target Price | 0.3 | |||
| Number Of Employees | 30 | |||
| Beta | 1.38 | |||
| Market Capitalization | 2.63 M | |||
| Total Asset | 42.15 M | |||
| Retained Earnings | (855.95 M) | |||
| Working Capital | 26.67 M | |||
| Current Asset | 254.7 M | |||
| Current Liabilities | 70.06 M | |||
| Z Score | -29.4 | |||
| Net Asset | 42.15 M |
About Infinity Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Infinity Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Infinity Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Infinity Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Infinity Stock
If you are still planning to invest in Infinity Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Infinity Pharmaceuticals' history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |